Sector Expert: George Zavoico

B. Riley FBR

Image: George Zavoico

Dr. George Zavoico, a senior equity analyst and senior vice president with B. Riley FBR, has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. Previously, Zavoico was a senior equity analyst at JonesTrading Institutional Services LLC, a senior equity research analyst in the healthcare sector at MLV & Co., and an equity analyst at Cantor Fitzgerald and Westport Capital Markets. Prior to becoming an equity analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector.

Subscribe to
Streetwise Reports

Companies Commented On

  • Abeona Therapeutics Inc.
  • Actinium Pharmaceuticals Inc.
  • ArQule Inc.
  • BioSpecifics Technologies Corp.
  • Blueprint Medicines Corp.
  • Catalyst Biosciences Inc.
  • Edge Therapeutics Inc.
  • Epizyme Inc.
  • Karyopharm Therapeutics Inc.
  • Loxo Oncology Inc.
  • OncoMed Pharmaceuticals Inc.
  • Pieris Pharmaceuticals Inc.
  • Sorrento Therapeutics Inc.
  • Stemline Therapeutics Inc.
  • Syndax Pharmaceuticals Inc.
  • Synergy Pharmaceuticals Inc.
  • Syros Pharmaceuticals
  • Threshold Pharmaceuticals Inc.
  • WAVE Life Sciences Ltd.

Recent Interviews

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17 (7/13/17)

If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them.

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market (4/19/17)

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.

2017 Small-Cap Biotech Watchlist: Takeaways for Investors (1/18/17)

Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.

Recent Quotes

"DRRX's new formulation of oxycodone, Remoxy, has made it very difficult for abusers to extract the active ingredient to get a concentrated hit of the pill's payload."

The Life Sciences Report with George Zavoico (4/13/16)
more >

"SNSS is going after registration for vosaroxin in the European Union."

The Life Sciences Report Interview with George Zavoico (4/6/16)
more >

"After seeing the complete data set from ASSURE and other studies of RVX-208, a lot of key opinion leaders are behind RVX's drug candidate."

The Life Sciences Report Interview with George Zavoico (4/6/16)
more >

"We expect to see reports on safety and efficacy from the first cohort of AST's cervical spinal cord injury trial starting sometime in Q2/16."

The Life Sciences Report Interview with George Zavoico (1/27/16)
more >

"Durable survival was reported in AST's small Phase 2 trial in acute myeloid leukemia."

The Life Sciences Report Interview with George Zavoico (12/16/15)
more >

"We are maintaining our Buy rating for AST."

— George Zavoico, JonesTrading (11/10/15)
more >

"We are initiating coverage of AST."

— George Zavoico, JonesTrading (10/8/15)
more >

"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases."

The Life Sciences Report Interview with George Zavoico (6/24/15)
more >

Due to permission requirements, not all quotes are shown.